Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02716038 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC
A Phase 2 study, sponsored by Columbia University.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT02716038 is a Phase 2 study that has completed, run by Columbia University. The registered enrollment target is 39 participants.
The verdict
NCT02716038, a Phase 2 study, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer. The study aims to determine if chemotherapy combined with immune-based therapy can lead to improvement in tumor response rates over historical response rates with chemotherapy alone.
Interventions
- DRUG Carboplatin
- DRUG Nab-paclitaxel
- DRUG MPDL3280A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2016-06-07 |
| Est. Completion | 2022-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02716038
The ClinicalTrials.gov registry entry for NCT02716038 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Carboplatin is the first listed.
NCT02716038 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02716038 about?
NCT02716038 is a clinical study titled "Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC". This is a research study to test the effectiveness of nab-paclitaxel + carboplatin + MPDL3280A for treatment of non-small-cell lung carcinoma (NSCLC), which is a type of lung cancer. The study aims to determine if chemotherapy combined with immune-based therapy can lead to improvement in tumor respo...
What is the current status of trial NCT02716038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2016-06-07. Estimated completion is 2022-10-01.
What interventions are being tested in trial NCT02716038?
The interventions under investigation include: Carboplatin (DRUG), Nab-paclitaxel (DRUG), MPDL3280A (DRUG).
Who is sponsoring clinical trial NCT02716038?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.